Related Experiment Video
Updated: Jun 24, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
[Chagas disease: clinical aspects and treatment in non-endemic countries]
Guillaume Le Loup1, Francois-Xavier Lescure, Michel Develoux
1Clinique du voyage et des maladies d'importation, Service des maladies infectieuses et tropicales, Hôpital Tenon, AP-HP, F-75020 Paris, France. guillaume.le-loup@tnn.aphp.fr
Abstract:
International migration has led to the emergence of Chagas disease in industrialized countries, notably France. Clinicians should consider and test for Chagas disease in several situations: chronic cardiac and digestive manifestations in patients who lived (or whose parents lived) in an endemic area; pregnant woman who come from an endemic area and in the infant if the mother's serologic tests are positive; and more rarely, patients with a persistent fever who recently visited an endemic area. During the acute phase, diagnosis is confirmed by parasitological testing. During the chronic phrase, diagnosis remains serologic. The usefulness of PCR has not been determined. The recent recognition of the parasite's pathogenic role during the chronic phase has enlarged the indications for treatment. Today, all patients younger than 50 years with Chagas disease in the acute, chronic symptomatic or chronic asymptomatic phases should receive treatment, except for pregnant women, patients with hepatic or renal failure, or advanced cardiac or digestive manifestations. Treatment must be considered on an individual basis in patients older than 50 years. The frequency and seriousness of potential adverse events due to treatment require careful monitoring of the patient throughout treatment.
Related Concept Videos
American Trypanosomiasis
Toxoplasmosis
Cholera
Leishmaniasis
Malaria
Giardiasis

